TrialCell reports. Medicine2024

Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma.

Michael Amatangelo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.